SOLICITATION NOTICE
A -- Process Development and Small Scale Manufacturing pharmaceutical entities. Must be cGMP and and GLP compliant.
- Notice Date
- 10/21/2004
- Notice Type
- Solicitation Notice
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- US Army Space and Missile Defense Command, Deputy Commander, ATTN SMDC-CM-AP, P.O. Box 1500, Huntsville, AL 35807-3801
- ZIP Code
- 35807-3801
- Solicitation Number
- W9113M-05-R-0001
- Response Due
- 12/22/2004
- Archive Date
- 2/20/2005
- Small Business Set-Aside
- N/A
- Description
- This synopsis updates work efforts and replaces solicitation number W9113M-04-R-0009. Prospective offerors responding to the synopsis for W9113M-04-R-0009 do not need to request to receive a solicitation again; names of interested parties are on fil e and a copy of the solicitation will be emailed to you when it is available. The US Army, Space and Strategic Defense Command, Chemical Biological Medical Systems intends to solicit and award a task order contract planned for a period of five years. The requirements consist of process development and small-scale manufacturing (2-10kg) in accordance with current Good Manufacturing Practices (cGMP) regulations and guidelines. These pharmaceutical entities do not include products derived from human source plasma or any recombinant products. The pharmaceuticals envisioned include products that have previously demonstrated effectiveness in the prophylaxis and/or treatment of injuries induced by chemical and biological warfare agents and radiation in animal m odels. Process development and manufacturing efforts would be directed at ensuring the availability of required starting materials and the improvement of synthesis/ manufacturing processes to achieve consistent high quality compounds and high yields that have shown promise as candidate antidotes against a broad spectrum of chemical warfare nerve agents. The products to be developed first are two oximes which have demonstrated effectiveness in the treatment of injuries induced by chemical warfare agents in animal models. Future compounds may include candidate drugs for the treatment of vesicant agent injuries. No paper copies of the solicitation will be made available. An RFP is anticipated to be available on or before 17 Nov 04. To request a copy of th e RFP, please contact Claudia Addison by email at claudia.addison@det.amedd.army.mil. This procurement is under full and open competition with no set-asides.
- Record
- SN00697467-W 20041023/041021212032 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |